调整 B 细胞淋巴瘤中 Polatuzumab Vedotin 的反应。
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
发表日期：2024 Sep 04
作者：
Etienne Leveille, Shalin Kothari, Kadriye N Cosgun, Coraline Mlynarczyk, Markus Müschen
来源：
Cancer Discovery
摘要：
Polatuzumab vedotin 是一种靶向 CD79B 的抗体药物偶联物，是二十多年来第一个被批准用于弥漫性大 B 细胞淋巴瘤一线治疗的新药，尽管决定 polatuzumab vedotin 治疗反应的因素仍不清楚。两项新研究确定了敏感性较低的核心机制，即通过 CD79B 的 N 连接糖基化降低 CD79B 表位的可及性，以及由于 KLHL6 E3 连接酶的活性而降低 CD79B 表面表达水平。请参阅 Corcoran 等人的相关文章，第 17 页。 1653 (6) 参见 Meriranta 等人的相关文章。 (7).©2024 美国癌症研究协会。
Polatuzumab vedotin, an antibody-drug conjugate targeting CD79B, is the first new drug approved for first-line therapy of diffuse large B-cell lymphoma in more than two decades, although factors determining treatment responses to polatuzumab vedotin remain unknown. Two new studies identified central mechanisms of lower sensitivity, namely reduced accessibility of the CD79B epitope through N-linked glycosylation of CD79B and lower CD79B surface expression levels due to the activity of the KLHL6 E3 ligase. See related article by Corcoran et al., p. 1653 (6) See related article by Meriranta et al. (7).©2024 American Association for Cancer Research.